Skip to main content

Fisher Scientific Products and Services Revenue Jumps 42 Percent in Third Quarter

NEW YORK, Nov. 4 (GenomeWeb News) - Fisher Scientific today said that third-quarter revenues increased 42 percent, which includes a 50-percent rise in revenue from scientific products and services.

Fisher Scientific's third-quarter revenues swelled to $1.2 billion from $890 million in the third quarter of 2003. Revenues from scientific products and services rose to $945 million from $632 million year over year.


Sales of scientific products and services in the recent quarter totaled $922.8 million, an increase of 46 percent compared to the third quarter of 2003.


Apogent and Oxoid, the company's molecular biology-supply unit, and Dharmacon, a recent acquisition, contributed revenue to Fisher's scientific products and services income. However, the Hampton, NH-based firm did not break out revenues by unit.


Net income dropped to $10.8 million, or $.10 per diluted share, from $27.7 million, or $.47 per share, year over year.


Fisher reported $296.4 million in cash and cash equivalents available on Sept. 30, part of the company's $7.9 billion of total assets.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.